a public good project by the
Synthesis
Company
of California

© 2026

Kenneth B. Gordon | doi.page

0 works0 citations0 h-index

Kenneth B. Gordon

Medical College of Wisconsin(US)Icahn School of Medicine at Mount Sinai(US)

Publications by Year

Research Areas

Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Asthma and respiratory diseases, Health Systems, Economic Evaluations, Quality of Life

Most-Cited Works

→ Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)(2008)1,859 cited
→ Guidelines of care for the management of psoriasis and psoriatic arthritis(2008)1,202 cited
→ Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics(2019)880 cited
→ Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial(2007)872 cited
→ Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis(2016)822 cited
→ Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis(2015)792 cited

→ Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial(2017)

718 cited

→ Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)(2015)659 cited

→ Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials(2018)639 cited